-+ 0.00%
-+ 0.00%
-+ 0.00%

Neola Medical Q3 operating loss widens 18% to SEK 3.33 million

PUBT·11/18/2026 07:00:17
Listen to the news
Neola Medical Q3 operating loss widens 18% to SEK 3.33 million
  • Neola Medical’s third-quarter operating loss widened 18% to SEK 3.33 million.
  • Cash flow swung to an inflow of SEK 17.05 million from an outflow of SEK 4.39 million.
  • Neola received FDA Breakthrough Device Designation in September, enabling prioritized regulatory engagement but not constituting market approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neola Medical AB published the original content used to generate this news brief on November 18, 2026, and is solely responsible for the information contained therein.